Biotech | May 23, 2022
Soligenix receives US patent allowance for its thermostabilized vaccine platform
Includes thermostabilized Ebola vaccines
Includes thermostabilized Ebola vaccines
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Subscribe To Our Newsletter & Stay Updated
